31P A global examination of clinical trials for patients with salivary gland cancers: An in-depth review of international registries and current challenges
Clinical trials (CTs) are crucial for improving the level of scientific evidence and clinical outcomes, but can be challenging in rare subtypes of cancers. Salivary Gland Cancers (SGC) are rare and highly heterogenic tumours, lacking approved systemic therapies and good responses. Their rarity and usual absence of centralized management significantly reduces the chances to develop CTs. We performed a descriptive analysis of SGC CTs to map the landscape of CT activity for patients with SGC.
Authors
- Robert L. Metcalf
- Ben O’Leary (ORCID: https://orcid.org/0000-0002-1092-9169)
- Pablo Jiménez Labaig
- M.D. Forster
- L. Lorini
- Cristina Gurizzan (ORCID: https://orcid.org/0000-0003-3030-2635)
- P. Bossi
- Kevin Joseph Harrington (ORCID: https://orcid.org/0000-0002-6014-348X)
- E. Kinloch
- Irene Braña (ORCID: https://orcid.org/0000-0002-1068-9601)
- Enriqueta Felip (ORCID: https://orcid.org/0000-0002-7620-0098)
- Renata Ferrarotto
- Shelley Burton
- G.J. Hanna
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Institute of Cancer Research (GB)
- Royal Hospital Chelsea (GB)
- London International Development Centre (GB)
- London Cancer (GB)
- Dana-Farber Cancer Institute (US)
- Royal Marsden Hospital (GB)
- Vall d'Hebron Hospital Universitari (ES)
- The Christie NHS Foundation Trust (GB)
- UCL Biomedical Research Centre (GB)
- IRCCS Humanitas Research Hospital (IT)
- University College London (GB)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104341
- Primary Topic
- Salivary Gland Tumors Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00